Before the widespread adoption of M22, clinical laboratories spent massive amounts of time, labor, and financial resources testing every single batch of culture media entering the facility. M22 introduced a data-driven, risk-based approach, demonstrating that certain highly stable media rarely fail when produced under stringent Good Manufacturing Practices (GMP). Key Concepts and Classifications in M22-A3
Last updated: [Current Year]. Always verify that you have the most recent edition of CLSI M22, as standards are revised approximately every 5–7 years.
The Clinical and Laboratory Standards Institute (CLSI) M22-A3 document is the global gold standard for quality control (QC) of commercially prepared microbiological culture media. For clinical laboratories, implementing these guidelines is essential to ensure diagnostic accuracy, regulatory compliance, and patient safety.
Labs that regularly need multiple CLSI standards can purchase an annual subscription. This gives access to the entire CLSI database, including M22-A3, as readable PDFs (non-downloadable but printable for lab use). clsi m22a3 pdf
The third edition (M22-A3) introduced several significant updates and clarifications:
If you have landed on this article searching for the , you are likely a:
CLSI M22-A3 is the third edition of the approved standard that establishes guidelines for the quality control of commercially prepared microbiological culture media. Published to streamline laboratory workflows while maintaining high safety standards, this document defines which types of media require rigorous user verification and which can be accepted based on the manufacturer’s quality certification. The Problem it Solved Before the widespread adoption of M22, clinical laboratories
Mycobacteria, such as Mycobacterium tuberculosis, are notorious for their slow growth rates and resistance to many antimicrobial agents. Nocardioform bacteria, like Nocardia asteroides, are commonly found in soil and can cause infections in humans, particularly in immunocompromised individuals. Other actinomycetes, such as Streptomyces and Actinomadura, are also known to cause infections in humans.
This section defines the document's purpose, which is to provide quality control information for commercially prepared microbiological culture media to both users and manufacturers. It also introduces the foundational premise that retesting is unnecessary for media of proven reliability.
While the CLSI M22-A3 guideline provides a comprehensive framework for susceptibility testing, there are challenges and limitations to its implementation. Some of the key challenges include: Always verify that you have the most recent
The full title of this document is: "Liquid Chromatography in the Clinical Laboratory; Approved Guideline—Third Edition."
While CLSI M22-A3 significantly reduces laboratory workload, implementation requires diligence: